Prostatic cancer screening (III) : Risk factors, natural history, course without treatment, characteristics of the cancers detected;Dépistage du cancer de la prostate (III) : Facteurs de risque, histoire naturelle, évolution sans traitement. Caractéristiques des cancers dépistés

Progres en Urologie

Volumn 7, Issue 4, 1997, Pages 655-661

  Villers, Arnauld ^a   Soulié, Michel ^b   Haillot, Olivier ^c   Boccon Gibod, Laurent ^d  

^a Clinique Esquirol   (France)

^b CHU RANGUEIL   (France)

^c CHU BRETONNEAU   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Diagnosis; Epidemiology; Natural history; Prostate cancer

Indexed keywords

AGE DISTRIBUTION; AGED; DISEASE COURSE; FRANCE; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PREVALENCE; PROSTATE TUMOR; REVIEW; RISK FACTOR; SURVIVAL;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FRANCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 1542485339     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. ADOLFSSON J., RONSTROM L., LOWHAGEN T., et al. Deferred treatment of clinically localize low grade prostate cancer : the experience from a prospective series at the Karolinska hospital. J. Urol, 1994, 152, 1757-1760.
2. APRIKIAN AG, BAZINET M., PLANTE M, ELHILALI M.M. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J. Urol., 1995, 154, 404-406.
3. AUS G., HUGOSSON J., NORLÉN L. Long-term survival and mortality in prostate cancer treated winth non curative intent. J. Urol., 1995, 154, 460-465.
4. BARON J.C., VILLERS A. Cancer de prostate stade T1 (Al, A2). Suivi à long-terme des cancers stade T1a. Etudes morphométriques : prédiction du cancer résiduel dans les stades T1. Prog. Urol., 1993, 2 Monographie, 24-29.
5. BARTHELEMY Y., GASMAN D., BELLOT J., CHOPIN D., ABBOU C. Valeur pronostique d'une unique biopsie prostatique échoguidée positive sur le volume tumoral et le caractére intracapsulaire de l'adénocarcinome prostatique. Prog. Urol., 1996, 920-925.
6. BOUFFIOUX C. L'étiologie du cancer de la prostate In : Urologie, Cancer de la Prostate. Edited by KHOURY S. and C. FIIS, 1988, 138.
7. BRENDLER C.B. Characteristics of prostate cancer found with early detection regimens. Urology, 1995, 46, 71-76.
8. CARTER B.S., BOVA G.S., BEATY T.H., STEINBERG G.D., WALSH P.C. Hereditary prostate cancer : Epidemiologic and clinical features. J. Urol., 1993, 150, 797-802.
9. CHODAK G.W., THISTED R.A., GERBE G.S. Results of conservative management of clinically localized prostate cancer. N. Eng. J. Med., 1994, 330, 242-248.
10. CIPOLLA B, VILLERS A., BARRON J.C., BOCCON-GIBOD L., MAILLOT O., MAZERON J.J., COLOMBEL M., RICHARD F., BELLOT J., DAUGE-GEFFROY M.C. Evolution "naturelle" du cancer de prostate localisé palpable (T2) "non traité". Prog. Urol., Monographie, 1993, 2, 19-23.
11. COLE P., MORRISON A.S. Basic issues in population screening for cancer. J.N.C.I., 1980, 64, 1263-1272.
12. Conférence de consensus : Le dépistage du cancer localisé de la prostate. Rapport et recommandations. Paris, 8-9 décembre 1989. Ann. Urol., 1990, 24, 5-8.
13. CUMMING J.A., RITCHIE A.W.S., GOODMAN C.M., et al. De-differentiation with Time in Prostate Cancer and the Influence of Treatment on the Course of the Disease. Br. J. Urol, 1990, 65, 271-274.
14. DANIEL H. A worse prognosis for smokers with prostate cancer. J. Urol, 1995, 154, 153-157.
15. EPSTEIN J.E., WALSH P.C., BRENDLER CB. Radical prostatectomy for impalpable prostate cancer; the John Hopkins experience with tumors found on transurethral resection (stage T1 and T1b) and on needle biopsy (stage T1c). J. Urol, 1994, 152, 1721-1729.
16. EPSTEIN J.E., WALSH PC, CARMICHAEL M, BRENDLER C.B. Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. J.A.M.A., 1994, 271, 368-374.
17. EPSTEIN J.E., PIZOV G., WALSH P.C. Correlation of Pathologic Findings with Progression after Radical Retropubic Prostatectomy. Cancer. 1993, 71, 3582-3593.
18. FRANKS L.M. Latent carcinoma of the prostate. J. Path. Bact., 1954, 603-615.
19. GHANADIAN R., PUAH C.M., O'DONOGHUE P.N. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 1979, 39, 696-699.
20. GILLILAND F.D., KEY C.R. Male genital cancers. Cancer, 1995, 75, 295-315.
21. GIOVANNUCCI E. Epidemiologic characteristics of prostate cancer. Cancer, 1995, 75, 1766-1777.
22. GROSCLAUDE P., MENEGOZ F., SCHAFFER P., MASSELESEC'H J., LE MAB G., ARVEUX P., SOULIE M, V. A: Le cancer de la prostate est il un problème de santé publique ? Actualisation des chiffres d'incidence, de mortalité en France de 1982 à 1990. Prog. Urol., 1997 (soumis).
23. HANCHETTE C.L., SCHWARTZ G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer, 1992, 70, 2861-2869.
24. HEALY B.: Does vasectomy cause prostate cancer. J.A.M.A., 1993, 269, 2620-2622.
25. HENDERSON B.E., ROSS R.K., PIKE M.C., CASAGRANDE D.F. Endogenous hormones as a major factor in cancer. Cancer Res., 1982, 42, 3232-3239.
26. HUMPHREY P.A, CATALONA W.J. Clinical and pathological findings of non-palpable prostate cancers. J. Uro, 1996, 155, 816-820.
27. KABALIN J.N., MCNEAL J.E., PRICE H.M., et al.: Unsuspected adenocarcinome o à f the prostate in patients undergoing cystoprostatectomy for other causes : incidence, histology and morphometric observations. J. Uro., 1989, 141, 1091-1094.
28. KEY T. Risks factors for prostate cancer. Cancer Surveys, 1995, 23, 63-77.
29. LEVI F., LUCCHINI F., LA VECCHIA C. Worldwide patterns of cancer mortality, 1985-1989. Eur. J. of Cancer Prevention, 1994, 343, 109-143.
30. MCNEAL J E., BOSTWICK D.G. Intraductal Dysplasia : a premalignant lesion of the prostate. Hum. Pathol., 1986, 17, 64-71.
31. MCNEAL J.E., VILLERS A. REDWINE E.A., et al. Capsular penetration in prostate cancer : Significance for natural history and treatment. Am. J. Surg. Pathol., 1990, 14, 240-247.
32. MCNEAL J.E., VILLERS A., REDWINE A.,et al. Histologic differenciation cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 1990, 66, 1225-1233.
33. MC WHORTER W.P., HERNANDEZ A.D., SMITH J.A., EYRE H.J. A screening study of prostate cancer in high risk families. J. Urol., 1992, 148, 826-828.
34. MEIKLE A.W., SMITH J.A., WEST D. W. Familial factors affecting prostatic cancer risk and plasma sex-steroïd levels. The Prostate, 1985, 6, 121-128.
35. METTLIN C.J., SELENKAS S., NATARAJAN N., HUBEN R. Beta-carotene and animal fat and their relationship to prostate cancer risk. Cancer, 1989, 64, 605-612.
36. NOMURA A.M.Y., KOLONEL N. Prostate cancer : current perspective. American J. Epidemiol., 1991, 13, 200-227.
37. OESTERLING J.E, SUMAN V.J, ZINCKE H, BOSTWICK D.G. PS-detected (clinical stage T1c of BO) prostate cancer. Urol. Clin. North Am., 1993, 20, 667-693.
38. OHORI M., WHEELER T.M., DUNN J.K., STAMEY T.A., SCARDINO P.T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol., 1994, 152, 1714-1720.
39. OTNES B., HARVEI S., FOSSA S.D. The burden of prostate cancer from diagnosis until death. Br. J. Urol., 1995, 76, 587-594.
40. PEARSON J.D., CARTER H.B. Natural history of changes in prostate specific antigen in early stage prostate cancer. J. Urol., 1994, 152, 1743-1748.
41. RAVIV G., JANSSEN T., ZLOTTA A.R, DESCAMPS F., VERHE A., SCHULMAN C.C. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J. Urol., 1996, 156, 1050-1055.
42. SAITOH H., HIDA M., SHIMBO T., et al. Metastatic Patterns of Prostatic Cancer : Correlation Between Sites and Number of Organs Involved. Cancer, 1984, 54, 3078-3084.
43. SAKR W. A., HAAS G.P., CASSIN B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol., 1993, 150, 379-385.
44. SCALETSCKY R., KOCH M.O., ECKSTEIN C.W., BICKNELL S.L., GRAY G.F., SMITH J.A. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J. Urol., 1991, 152, 129-131.
45. SCHMIDT H.P, MCNEAL J.E., STAMEY T.A., et al. Observations on the Doubling Time of Prostate Cancer : The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 1993, 71, 2031-40.
46. SMITH D.S., CATALONA W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 1994, 152, 1732-1736.
47. STEINBERG G.D., CARTER B.S., BEATY T.H., CHILDS B.,WALSH P.C. Family history and the risk of prostate cancer. The Prostate, 1990, 17, 337-347.
48. STAMEY T. A., FREIHA F. S., MC NEAL J. E., REDWINE E. A., WHITTEMORE A. S., SCHMID H. P. Localized prostate cancer, relationship of tumor volume to clinical significance for traitement of prostate cancer. Cancer, 1993, 71, 933-938.
49. TULINIUS H., EGILSSON V., OLAFSDOTTIR H. et al. Risk of prostate, ovarian, and endometrial cancer amongrelatives of women with breast cancer. Brit. Med. J., 1992, 305, 855-857.
50. VALERI A., BERTHON P., FOURNIER G. et al. Etude Progène, projet français d'analyse génétique du cancer de la prostate familial : recrutement et analyse. Prog. Urol., 1996, 6, 226-235.
51. VILLERS A., MCNEAL J.E., FREIHA F.S., STAMEY T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer, 1992, 70, 2313-2318.
52. VILLERS A., G. P., SOULIE M., HAILLOT O Dépistage du cancer de la prostate : évolutions des connaissances et des pratiques depuis la conférence consensus de 1989. Adressé pour publication, 1997.
53. WATERBOR J. W., BUESCHEN A.J. Prostate cancer screening (United States). Cancer causes and control, 1995, 6, 267-274.
54. WEINSTEIN M.S., EPSTEIN J.I. Significance of high grade prostatic intraepitelial neoplasia on needel biopsy. Human Pathol., 1993, 24, 624-629.
55. WILSON J.M.G., JUNGER G. Principles and practice of screening of disease, Geneva : World organisation. Public Health Paper, 1986, 34.
56. WITHMORE W.F., WARNER J.A., THOMPSON I.M. Expectant management of localized prostatic cancer. Cancer, 1991, 67, 1091-1096.